Table 3.

Univariate and multivariate analysis

		Univariate analysis		Multivariate analysis
Covariates	Comparisons	Median PFS in months (95% CI)	P‐value	P‐value	HR (95% CI)
Gender	Male vs. female	1.70 (0.00–4.94) vs. 3.25 (1.65–4.86)	0.820
ECOG PS	1 vs. 2	3.25 (0.00–6.61) vs. 1.81 (0.22–3.40)	0.225
Smoking status	Never vs. ever	2.69 (0.99–4.40) vs. NR	0.168
Tumor stage	IVB vs. IVA	1.38 (0.91–1.85) vs. 2.69 (1.42–3.96)	0.452
	IVC vs. IVA	3.42 (0.92–5.92) vs. 2.69 (1.42–3.96)	0.857
Brain metastasis	Present vs. absent	2.69 (1.00–4.39) vs. 4.63 (0.45–8.82)	0.397
Liver metastasis	Present vs. absent	2.04 (0.49–3.59) vs. 3.42 (0.88–5.96)	0.031	0.041	2.96 (1.05–8.34)
EGFR gene mutation	EGFR L858R vs. EGFR 19del	5.52 (0.00–11.24) vs. 2.04 (1.32–2.76)	0.284
EGFR T790M status	Positive vs. negative	2.69 (1.20–4.19) vs. 3.42 (0.98–5.85)	0.893
PD‐L1 status	1%–50% vs. ≥50%	NA vs. 6.14 (2.19–4.63)	0.771
	Negative/unknown vs. ≥ 50%	2.69 (0.76–4.63) vs. 6.14 (2.19–10.10)	0.348
Local therapy	Yes vs. no	1.58 (1.33–1.83) vs. 2.10 (0.00–4.47)	0.762
Prior chemotherapy	Yes vs. no	3.25 (1.22–5.28) vs. 2.10 (1.93–2.27)	0.736
Prior antiangiogenic drugs therapy	Yes vs. no	3.42 (0.97–5.87) vs. 1.58 (0.80–2.35)	0.027	0.023	0.27 (0.09–0.83)
Immunotherapy regimens	Combination therapy vs. monotherapy	3.42 (1.94–4.90) vs. 1.61 (1.33–1.89)	0.078	0.044	0.346 (0.12–0.97)